OPKO Health to build and configure integrated data capture and drug safety systems
OPKO Health, Inc., a multinational pharmaceutical & diagnostics company, has selected DSG’s eCaseLink integrated suite for self-building of harmonized electronic data capture (EDC), IWRS, drug safety event capture and case reporting, and CTMS systems. DSG’s team will support the OPKO team and their Site users 24 x 365.
DSG’s Drug Safety, a comprehensive adverse event management system developed by DSG as part of an integrated suite including EDC, IWRS, and CTMS, streamlines the safety recording, reporting process, data entry on Serious Adverse Events (SAEs), storing associated documents facilitating the generation and tracking of queries. Features include integration with other regulatory and management systems, ICH E2B compliance, and generating FDA 3500A MedWatch and CIOMS forms, exporting data as required. Sponsors configure the system to accommodate unique workflows and procedures more efficiently.
DSG’s flagship EDC software, eCaseLink™, in continuous use since 1999, provides system builders with an intuitive tool, DSG Designer, enabling unlimited quantities of cross-visit edits on eCRFs without compromising system performance, a proprietary technology unique to DSG. Other helpful features include risk-based monitoring, 3rd-party system data integration, module for managing local lab Normals, integrated MedDRA/WHO drug auto-interactive encoder, ad-hoc reporting, SAS datasets on demand, patient profiles, protocol deviations, image upload and management, unlimited auto-emails, auto-population between eCRFs, Innovation Award-winning IWRS and also Data Management dashboard, integrated training modules, with round-the-clock support from DSG, one of the industry’s oldest and most experienced EDC providers.
“We are very pleased to be working with OPKO Health,” said Tony Varano, CEO of DSG, Inc, “and are excited to partner with and support such an experienced and talented multinational team with our technology.”
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.